Spire Wealth Management lessened its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 23.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange ...

Edwards Lifesciences Corp. closed 26.14% below its 52-week high of $96.12, which the company reached on March 28th.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.55 per share, reflecting a decline of 14.1% compared to the same period last ...

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...